2024-10-30 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**1. Performance Comparison and Relative Strength:**

Eli Lilly and Co. (LLY) has significantly outperformed the S&P 500 (VOO) with a cumulative return of 869.34% compared to 136.74% for the benchmark index. The absolute return difference is 732.6, which represents 90.96% of the maximum historical difference between the two stocks. This suggests that LLY's performance has been exceptionally strong relative to the broader market.

**2. Recent Price Action:**

* **Closing Price:** $903.58 (Last Market: $904.05)
* **5-Day Moving Average:** $897.29
* **20-Day Moving Average:** $906.72
* **60-Day Moving Average:** $911.72

The stock is currently trading slightly below its 5-day and 20-day moving averages, indicating a minor short-term correction. However, it remains above the 60-day moving average, suggesting a potential for further upside.

**3. Technical Indicators:**

* **RSI:** 41.82
* **PPO:** -0.18
* **Delta_Previous_Relative_Divergence:** 1.82 (+) - Short-term upward momentum
* **Expected Return:** 48.57%

The RSI is in the neutral zone, indicating neither overbought nor oversold conditions. The negative PPO suggests a weakening momentum, but the positive Delta_Previous_Relative_Divergence hints at a potential short-term rebound. The expected return of 48.57% suggests a potentially strong long-term performance, potentially exceeding the S&P 500.

**4. Recent Earnings and Outlook:**

| Date       | EPS      | Revenue      |
|------------|----------|--------------|
| 2024-08-08 | 3.29     | $11.30 B$     |
| 2024-04-30 | 2.49     | $8.77 B$     |
| 2023-11-02 | -0.06     | $9.50 B$     |
| 2023-08-08 | 1.96     | $8.31 B$     |
| 2024-08-08 | 1.96     | $8.31 B$     |

The latest earnings report for the quarter ended 2024-08-08 showed a significant increase in both EPS and revenue compared to the previous quarter. This positive trend indicates strong growth for the company. Although specific analysts' estimates are not provided, the strong performance suggests potential for exceeding expectations.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|-----------|---------------|
| 2024-06-30 | $11.30B  | 80.80%       |
| 2024-03-31 | $8.77B   | 80.91%       |
| 2023-12-31 | $9.35B   | 80.88%       |
| 2023-09-30 | $9.50B   | 80.42%       |
| 2023-06-30 | $8.31B   | 78.26%       |

The company consistently demonstrates high profitability with consistently strong profit margins over the past several quarters, reflecting efficient operations and strong market position.

**2) Capital and Profitability:**

| Quarter      | Equity    | ROE        |
|--------------|-----------|-------------|
| 2024-06-30 | $13.56B  | 21.88%     |
| 2024-03-31 | $12.81B  | 17.51%     |
| 2023-12-31 | $10.77B  | 20.33%     |
| 2023-09-30 | $11.22B  | -0.51%      |
| 2023-06-30 | $11.06B  | 15.94%     |

High and consistent ROE indicates a strong return on invested capital and the company's ability to generate profits effectively.  However, a negative ROE in Q3 2023 should be investigated. 

**6. News and Recent Issues:**

Please provide the exact date of the earnings announcement for 2024-08-08. With this information, I can access specific news and analyst reports related to the recent earnings release from sources like Shacknews, FINBOLD, and others. I can then provide detailed analysis on the market outlook, analyst opinions, and performance highlights.

**7. Overall Analysis:**

Eli Lilly and Co. (LLY) has consistently demonstrated robust performance with a high return compared to the S&P 500. Recent earnings indicate strong growth and profitability, further solidifying the company's positive outlook. Technical indicators suggest a potential short-term correction, but the overall trend remains bullish. The company's strong financials and consistent profitability suggest long-term potential for continued growth.

**Disclaimer:** This is a general analysis based on provided data. It does not constitute financial advice. Please conduct your own research and consult with a qualified financial advisor before making any investment decisions. 
